- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor vascular infarction: prospects and challenges
Authors
Keywords
Tumor vascular targeting, Tumor vascular infarction, Incomplete thrombosis, Tissue factor (TF), Novel strategy, MazF
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 105, Issue 3, Pages 244-256
Publisher
Springer Nature
Online
2017-01-02
DOI
10.1007/s12185-016-2171-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Broad targeting of angiogenesis for cancer prevention and therapy
- (2015) Zongwei Wang et al. SEMINARS IN CANCER BIOLOGY
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Regression of Solid Tumors by Induction of MazF, a Bacterial mRNA Endoribonuclease
- (2014) Tsutomu Shimazu et al. JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY
- CD4+ T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques
- (2014) Naoki Saito et al. Molecular Therapy-Nucleic Acids
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients
- (2013) J. E. Geddings et al. BLOOD
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
- (2013) Asmaa E El-Kenawi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice
- (2013) N. Yokota et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Sustained Inhibition of HIV-1 Replication by Conditional Expression of the E. coli-Derived Endoribonuclease MazF in CD4+ T cells
- (2013) Mika Okamoto et al. Human Gene Therapy Methods
- Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents
- (2013) Marta Cesca et al. Frontiers in Oncology
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
- (2011) O. Wahl et al. CURRENT MEDICINAL CHEMISTRY
- Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
- (2011) Angelo Corti et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Disrupting established tumor blood vessels
- (2010) Mark J. McKeage et al. CANCER
- Flipping the wound that doesn't heal: the upside of coagulation in cancer
- (2009) B. A. Teicher BLOOD
- Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience
- (2009) R. Bieker et al. BLOOD
- High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
- (2009) S. H. Kim et al. CANCER RESEARCH
- Tumor-Derived Tissue Factor-Bearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy
- (2009) J. I. Zwicker et al. CLINICAL CANCER RESEARCH
- Tumor-targeting prodrug-activating bacteria for cancer therapy
- (2008) C-M Cheng et al. CANCER GENE THERAPY
- Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy
- (2008) F. Friedlos et al. CLINICAL CANCER RESEARCH
- A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model
- (2008) Feng-ying Huang et al. Journal of Zhejiang University-SCIENCE B
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started